Reviewing Aevi Genomic Medicine Inc. (GNMX)’s and Vaccinex Inc. (NASDAQ:VCNX)’s results

Both Aevi Genomic Medicine Inc. (NASDAQ:GNMX) and Vaccinex Inc. (NASDAQ:VCNX) are Biotechnology companies, competing one another. We will contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aevi Genomic Medicine Inc. N/A 0.00 31.31M -0.53 0.00
Vaccinex Inc. N/A 90.70 24.47M -2.13 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Aevi Genomic Medicine Inc. and Vaccinex Inc.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Aevi Genomic Medicine Inc. 0.00% -152.1% -122%
Vaccinex Inc. 0.00% 0% 0%


The Current Ratio of Aevi Genomic Medicine Inc. is 3.1 while its Quick Ratio stands at 3.1. The Current Ratio of rival Vaccinex Inc. is 4.8 and its Quick Ratio is has 4.8. Vaccinex Inc. is better equipped to clear short and long-term obligations than Aevi Genomic Medicine Inc.

Insider & Institutional Ownership

Aevi Genomic Medicine Inc. and Vaccinex Inc. has shares held by institutional investors as follows: 19.7% and 2.2%. Insiders held roughly 30.2% of Aevi Genomic Medicine Inc.’s shares. On the other hand, insiders held about 5.6% of Vaccinex Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aevi Genomic Medicine Inc. 14.56% 2.61% 4.42% -16.31% -1.67% -1.67%
Vaccinex Inc. -6.08% -16% -46.59% 0% 0% -53.87%

For the past year Aevi Genomic Medicine Inc.’s stock price has smaller decline than Vaccinex Inc.


Vaccinex Inc. beats Aevi Genomic Medicine Inc. on 5 of the 7 factors.

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington's disease. The company's preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.